Article
At EULAR 2023, there was a late breaking abstract that compared difficult to treat patients with RA who had received treatment (including TNFi and JAKi in some patients) previously and still had active disease.
All News
Article
In my focus group consisting of people living with SLE and their carers, one of the keys issues raised by them was pertaining to poor reliable information about their condition. At the 2023 EULAR Congress in Milan, I learned about the wide scale dissemination and international launch of Lupus100.org project.
Article
Several studies were reported at EULAR2023 about Takayasu’s arteritis (vasculitis), a very rare large vessel vasculitis that occurs in young individuals.
Article
One of the primary questions about JAK inhibitor safety, ever since its first approval, has been the risk of herpes zoster.
Dr. John Cush
Tweet
Daily Recap: Day One + Two
https://t.co/USBFbTWzGG https://t.co/RV9RyLLNmX
Dr. John Cush
Tweet
Abatacept: is there a role before RA hits?
Dr. David Liew discusses OP0130 at EULAR 2023 in Milan, Italy.
https://t.co/XJXabAULhn https://t.co/Hv93HKolKH
Dr. John Cush
Tweet
Among 247.3 million US adults. 10.0% (20.3 million) had CVD & 56% were at risk for CVD. Yet only 3.6 million CVD (18%) & 34.5 million at risk for CVD (26%) used wearable devices (compared to 29% in US adults, but less than half wear every day. https://t.co/04xqtkw61x https://t.co/ETTjamvHi2
Dr. John Cush
Tweet
Watch: Zoster Management and Vaccination
Drs. Janet Pope and Kevin Winthrop at EULAR 2023 in Milan, Italy.
https://t.co/eOhXzw3Epy https://t.co/h3NoDggg5x
Dr. John Cush
Tweet
ANCA-associated vasculitis: beyond therapy with rituximab?
AAV is a group of multi-system autoimmune small vessel vasculitides which includes GPA, MPA and EGPA.
https://t.co/z8RgNYvBiO https://t.co/NI4z4kSAHQ
Dr. John Cush
Tweet
Methotrexate - an old trusted friend who deserves better
MTX has been used as the anchor drug for the treatment of RA and PsA for many years. It has been co-prescribed with biologics and JAKi in clinical trials and as well as in clinical practice.
https://t.co/rSHsysJQ46 https://t.co/OKfBiMlqyg
Dr. John Cush
Tweet
Congratulations to Professor Daniel Aletaha - the New EULAR President. Daniel Aletaha is the Professor and Head of the Division of Rheumatology at the Medical University Vienna https://t.co/NgLM4rk7Xd https://t.co/Z9XisPQb2M
Dr. John Cush
Tweet
Rheumatoid Arthritis, Radiomics and Interstitial Lung Disease
Drs. Antoni Chan and Vincenzo Venerito discuss abstracts OP0127 and POS0855 presented at EULAR 2023 in Milan, Italy.
https://t.co/SuMMrkwfvk https://t.co/hSSPKIW4Os
Dr. John Cush
Tweet
SLE Trial: Dual BTK JAK Blockade compared Upadacitinib Monotherapy
Dr. Yuz Yusof discusses abstract OP0139 presented at EULAR 2023 in Milan, Italy.
https://t.co/os1tyiDnuT https://t.co/G0owdGek7f
Dr. John Cush
Tweet
Difficult to treat RA is Actually Difficult to Define
Dr. Janet Pope discusses abstract OP0134 presented at EULAR 2023 in Milan, Italy.
https://t.co/0J9mH9n8jJ https://t.co/JT1hGp2S5w
Dr. John Cush
Tweet
How to avoid POLYPHARMACY (taking too many medicines). JAMA overview on DE-prescribing. https://t.co/MNmBuuhsFF https://t.co/HQwcsYwj3N
Dr. John Cush
Tweet
CV and Cancer Risk with JAK inhibitors
Dr. Jonathan Kay discusses abstract OP0132 presented at EULAR 2023 in Milan, Italy.
https://t.co/SZLohnNEa1 https://t.co/ZEv0Q2NSBf
Dr. John Cush
Tweet
Watch: SpA and Interstitial Lung Disease
Dr. Eric Ruderman discusses abstract OP0006 presented at EULAR 2023 in Milan, Italy.
https://t.co/wsR3gv1jSr https://t.co/ULYbJeoFHi
Dr. John Cush
Tweet
Efficacy and Safety of Baricitinib in Lupus Nephritis
Dr. Yuz Yusof discusses abstract OP0053 presented at EULAR 2023 in Milan, Italy.
https://t.co/ebQ5RwG2po
@Yuz6Yusof https://t.co/mUp7OXVK9K
Dr. John Cush
Tweet
Clinically suspect arthralgias: justified or artefact?
At #EULAR23, the perfect platform was provided for an airing of grievances, in a debate entitled ‘Clinically suspect arthralgias: fact or myth’.
Dr. Liew ( @drdavidliew ) summarizes the debate.
https://t.co/wxLQlTVIaZ https://t.co/F6dJDZBrDk
Dr. John Cush
Tweet
Are T cells the missing link in pre-clinical RA?
T cells are known to play a key role in RA pathogenesis and the diversity of the T cell repertoire is known to be reduced in RA.
Dr.Najm ( @AurelieRheumo ) shares #EULAR23 presentations on this topic.
https://t.co/qVyDp6Gs2y https://t.co/mqxNLIxShd
